A CRITICAL EVALUATION OF THE COMMONLY USED BIOCHEMICAL AND CELL-BASED ASSAYS


1



- 1. Overview of the Fraunhofer
- 2. The role of assays pre-clinical drug discovery
- 3. Evaluation of biochemical and cell-based assays

Overview of the Fraunhofer

The Fraunhofer-Gesellschaft




Fraunhofer Health Collaborations



Prevention research
Preventing childhood obesity



Prevention research National cohort to investigate the genesis of common diseases




Brain research Neuroprosthetics and deep-brain stimulation



Infection research The green biofactory in the fight against AIDS and malaria



Diabetes research Customized prevention and treatment



Cardiovascular research Gene variant determines cholesterol levels




Cancer research Treating cancer accurately with laser beams



Gerontology
Assistance systems for the home



Prevention research Identifying risks associated with medication



Biomedical engineering Developing diagnostic microsystems



Biomedical engineering Factory-made skin



Medical materials Metallic foam structures as a bone substitute

Capabilities of the Fraunhofer-IME

National



Applied Ecology Division Schmallenberg (1959)



Molecular Biology Division Aachen (2000)

International



Center for Molecular Biotechnology Newark, USA (2001)



Bioresources Gießen (2009)



Biopolymers Münster (2010)



TMP Frankfurt (2012)




ScreeningPort Hamburg (2014)



Center for Systems Biotechnology Santiago, Chile (2010)

Capabilities of the Fraunhofer-IME SP










The role of assays pre-clinical drug discovery

Drug discovery cascade



Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. How to improve R&D productivity: the pharmaceutical industry's grand challenge

Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacu R. Lindbora and Aaron I. Schacht

> NATURE REVIEWS DRUG DISCOVERY VOLUME 9 MARCH 2010 203

HTS in Big Pharma: small molecules

Table 2 Examples of recently approved drugs with origins in HTS hits				
Drug (US trade name; company)	Indication	Target class	Year HTS was run	Year of FDA approval
Gefitinib (Iressa; AstraZeneca)	Cancer	Tyrosine kinase	c. 1993	2003
Erlotinib (Tarceva; Roche)	Cancer	Tyrosine kinase	c. 1993	2004
Sorafenib (Nexavar; Bayer/Onyx Pharmaceuticals)	Cancer	Tyrosine kinase	1994	2005
Tipranavir (Aptivus; Boehringer Ingelheim)	HIV	Protease	c. 1993	2005
Sitagliptin (Januvia; Merck & Co)	Diabetes	Protease	c. 2000	2006
Dasatinib (Sprycel; Bristol-Myers Squibb)	Cancer	Tyrosine kinase	1997	2006
Maraviroc (Selzentry; Pfizer)	HIV	GPCR	1997	2007
Lapatinib (Tykerb; GlaxoSmithKline)	Cancer	Tyrosine kinase	c. 1993	2007
Ambrisentan (Letairis; Gilead)	Pulmonary hypertension	GPCR	c. 1995	2007
Etravirine (Intelence; Tibotec Pharmaceuticals)	HIV	Reverse transcriptase	c. 1992	2008
Tolvaptan (Samsca; Otsuka Pharmaceutical)	Hyponatraemia	GPCR	c. 1990	2009
Eltrombopag (Promacta; GlaxoSmithKline)	Thrombocytopaenia	Cytokine receptor	1997	2008

Dragan A. Cirovic is at the Department of Lead Generation and Candidate Realization, Sanofi-Aventis, 1041 Route 202-206, Mail Stop BRJR1-002A, Bridgewater, New Jersey 08807, USA.

Tina Garyantes is at the Department of Lead Generation and Candidate Realization, Sanofi-Aventis, 1041 Route 202-206, P.O. BOX 6800, JR-303D, Bridgewater, New Jersey 08807, USA.

Darren V. S. Green is at the Department of Computational and Structural Chemistry, GlaxoSmithKline, Stevenage, Hertfordshire SG 1 2NY. UK.

> Jeff W. Paslay was previously at the Department of Screening Sciences, Research Centers of Emphasis, Pfizer; Present address: 302 Old Barn Circle, Phoenixville, Pennsylvania 19460, USA.

Ulrich Schopfer is at the Lead Finding Platform, Novartis Institutes for BioMedical Research, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland.

G. Sitta Sittampalam is at the Department of Pharmacology, Toxicology & Therapeutics, Institute for Advancing Medical Innovations, The University of Kansas Cancer Center, 3901 Rainbow Blvd., Kansas City, Kansas 66160, USA.

Darren V. S. Green is at the Department of Computational and Structural Chemistry, GlaxoSmithKline, Stevenage, Hertfordshire SG 1 2NY, UK.

Robert P. Hertzberg is at the Department of Screening and Compound Profiling, GlaxoSmithKline, Mail Stop UP 12-L05, 1250S Collegeville Rd, Collegeville, Pennsylvania 19426, USA.

William P. Janzen is at the Division of Medicinal Chemistry and Natural Products, Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, North Carolina 27599-7363, USA.

Martyn N. Banks is at the Department of Applied Biotechnologies, Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, Connecticut 06492, USA.

Dejan Bojanic is at the Lead Finding Platform, Novartis Institutes for Biomedical Research Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

David J. Burns is with the Early Pain Discovery Team, Abbott Laboratories, R4DI AP52N 200 Abbott Park Road, Abbott Park, Illinois 60064, USA. OPINION

Impact of high-throughput screening in biomedical research

Ricardo Macarron, Martyn N. Banks, Dejan Bojanic, David J. Burns, Dragan A. Cirovic, Tina Garyantes, Darren V. S. Green, Robert P. Hertzberg, William P. Janzen, Jeff W. Paslay, Ulrich Schopfer and G. Sitta Sittampalam

NATURE REVIEWS DRUG DISCOVERY

188 MARCH 2011 VOLUME 10

Phenotypic screening & cancer drug discovery

Lead discovery




Figure 1 | **Origins of new small-molecule cancer drugs approved by the FDA between 1999 and 2013**. Kinase inhibitors are highlighted within the dotted boxes. Information on the drugs to be analysed was obtained from the <u>US Food and Drug Administration</u> (FDA) website. *First-in-class drug.

> ¹Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California 94080, USA. ³Department of Discovery Chemistry, Genentech, South San Francisco, California 94080, USA. ³IOTA Pharmaceuticals, SI Johns Innovation Centre, Cowley Road, Cambridge CBA OWS, UK.


Phenotypic screening in cancer drug discovery — past, present and future

NATURE REVIEWS DRUG DISCOVERY 588 | AUGUST 2014 | VOLUME 13

11

John G. Moffat¹, Joachim Rudolph² and David Bailey³

How may drug targets are there?







Table 1 Molecular targets of FDA-approved drugs		
Class of drug target	Species	Number of molecular targets
Targets of approved drugs	Pathogen and human	324
Human genome targets of approved drugs	Human	266
Targets of approved small-molecule drugs	Pathogen and human	248
Targets of approved small-molecule drugs	Human	207
Targets of approved oral small-molecule drugs	Pathogen and human	227
Targets of approved oral small-molecule drugs	Human	186
Targets of approved therapeutic antibodies	Human	15
Targets of approved biologicals	Pathogen and human	76



OPINION

John P. Overington and Bissan Al-Lazikani are at Inpharmatica Ltd., 1 New Oxford Street, London, WC1A 1NU, UK.


Andrew Hopkins is at Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ, UK.

How many drug targets are there?

John P. Overington, Bissan Al-Lazikani and Andrew L. Hopkins

NATURE REVIEWS DRUG DISCOVERY VOLUME 5 DECEMBER 2006 993

Realistic drug discovery cascade




Mitigating risk in academic preclinical drug discovery

NATURE REVIEWS DRUG DISCOVERY VOLUME 14 | APRIL 2015 | 279


Jayme L. Dahlin¹, James Inglese^{2,3} and Michael A. Walters⁴


Assay systems and High Throughput Screening

Example biochemical assay HTS output



Example ELISA HTS output





10

30

40



ARTICLE Received 27 Sep 2011 | Accepted 11 Jan 2012 | Published 21 Feb 2012

MRCT

Screen

0.70

45'000

0.024% (12)

12

0% (0)

An intrinsically labile α -helix abutting the BCL9-binding site of β -catenin is required for its inhibition by carnosic acid

Marc de la Roche¹, Trevor J. Rutherford¹, Deepti Gupta¹, Dmitry B. Veprintsev^{1,†}, Barbara Saxty², Stefan M. Freund¹ & Mariann Bienz¹

Example in silico output




Figure 1. Flow chart of virtual and experimental screening strategy for discovering EBNA1 inhibitors. The EBNA1/DNA crystal structure was computationally fitted into a 6 Å grid containing every residue of the EBNA1 DNA-binding pocket was used to dock a library of compounds from the SPECS database. Compounds were preselected for solubility in an aqueous solution using a log *S* value of greater than -4. A database of ~90,000 small-molecule compounds were then analyzed by one primary docking programs and three score functions to calculate the free energy of binding. 5000 candidates were then re-examined using Xscore, Slide, and AutoDock programs to select 30 top candidates. The top 30 compounds from 15 manually classified groups were selected for experimental DNA binding and cell-based bioassays.




Figure 3. Physical inhibition of EBNA1-DNA binding assays. Candidate inhibitors SC7, SC11, SC19, and SC27 were assayed by fluorescence polarization (FP) for inhibition of EBNA1-DNA binding (panel A) and for inhibition of Zta-DNA binding (panel B). IC50 values were calculated for each isothem. Inhibitor concentrations were diluted 2-fold from 833 to 7 μM for each compound. Inhibitors were also assayed using a secondary EMSA assay to monitor EBNA1-DNA binding (panel C) or Zta-DNA binding (panel D) using the same concentrations of inhibitor compounds (two fold dilutions from 833 to 7 μM) as that shown for FP assays in panels A and B, above.

OPEN 🗟 ACCESS Freely available online	PLoS one
---------------------------------------	----------

Discovery of Selective Inhibitors Against EBNA1 via High Throughput *In Silico* Virtual Screening

Ning Li¹⁹, Scott Thompson²⁹, David C. Schultz², Weiliang Zhu¹, Hualiang Jiang¹, Cheng Luo¹*, Paul M. Lieberman²*

1 Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, 2The Wistar Institute, Philadelphia, Pennsylvania, United States of America

Example stem-cell based screen




Cell Stem Cell Resource

High-Throughput Screening Assay for the Identification of Compounds Regulating Self-Renewal and Differentiation in Human Embryonic Stem Cells

Sabrina C. Desbordes,^{1,2,8,*} Dimitris G. Placantonakis,^{2,5} Anthony Ciro,³ Nicholas D. Socci,⁴ Gabsang Lee,^{1,2} Hakim Djaballah,³ and Lorenz Studer^{1,2,*} Developmental Biology Program ³Department of Neuroscryery ⁴High-Throughput Screening Core Facility ⁴Computational Biology Center ^{Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA ⁵Department of Neurological Surgery, Weill Cornell Medical College, 525 East 68th Street, New York, NY 10021, USA ⁶Present address: Differentiation and Cancer Program, Centre de Regulació Genòmica, C/Dr. Aiguader 88, 08003 Barcelona, Spain Cell Stem Cell 2, 602–612, June 2008}

SUMMARY

High-throughput screening (HTS) of chemical libraries has become a critical tool in basic biology and drug discovery. However, its implementation and the adaptation of high-content assays to human embryonic stem cells (hESCs) have been hampered by multiple technical challenges. Here we present a strategy to adapt hESCs to HTS conditions, resulting in an assay suitable for the discovery of small molecules that drive hESC self-renewal or differentiation. Use of this new assay has led to the identification of several marketed drugs and natural compounds promoting short-term hESC maintenance and compounds directing early lineage choice during differentiation. Global gene expression analysis upon drug treatment defines known and novel pathways correlated to hESC self-renewal and differentiation. Our results demonstrate feasibility of hESC-based HTS and enhance the repertoire of chemical compounds for manipulating hESC fate. The availability of highcontent assays should accelerate progress in basic and translational hESC biology.




PCSK9 (protease) biochemical assay

Functional characterization of Narc 1, a novel proteinase related to proteinase K

Saule Naureckiene,^a Linh Ma,^a Kodangattil Sreekumar,^b Urmila Purandare,^{a,1} C. Frederick Lo,^a Ying Huang,^c Lillian W. Chiang,^{d,2} Jill M. Grenier,^{d,3} Bradley A. Ozenberger,^a J. Steven Jacobsen,^a Jeffrey D. Kennedy,^a Peter S. DiStefano,^{d,4} Andrew Wood,^a and Brendan Bingham^{a,*}

Archives of Biochemistry and Biophysics 420 (2003) 55-67

Substrate	Sequence	Relative activity (%)	
Subtilisin substrate	Z-GGL-AMC	4.5	
Furin substrate	Boc-RVRR-AMC	20	
TPP II substrate	H-AAF-AMC	1.4	
Processing site substra	tes		
SN-1	Dnp-FAQSIPK-AMC	100	
SN-2	Dnp-DSLVFAK-AMC	1.2	
SN-3	Dnp-FANAIPK-AMC	82	



However, PCSK9 is bound to its pro-domain and catalytically inactive

The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol


Derek E. Piper,¹ Simon Jackson,² Qiang Liu,³ William G. Romanow,¹ Susan Shetterly,² Stephen T. Thibault,⁴ Bei Shan,² and Nicel P.C. Walker^{1,+} Structure *15*, 545–552, May 2007

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia


David Cunningham¹, Dennis E Danley¹, Kieran F Geoghegan¹, Matthew C Griffor¹, Julie L Hawkins¹, Timothy A Subashi¹, Alison H Vanghse¹, Mark J Ammirati¹, Jeffrey S Culp¹, Lise R Hoth¹, Mahmoud N Mansour¹, Katherine M McGrath¹, Andrew P Seddon¹, Shirish Shenolikar², Kim J Stutzman-Engoall¹, Laurie C Warren¹, Donghui Xia¹ & Xiyang Qiu¹


NATURE STRUCTURAL & MOLECULAR BIOLOGY

VOLUME 14 NUMBER 5 MAY 2007 413




PCSK9: 12 years from target ID to drug





PCSK9 binding to the LDL receptor: • LDL receptor is degraded • less LDL can be removed from blood

Figure 2. PCSK9 can degrade the LDL receptor. If the LDL receptor is not bound to PCSK9, it can be recycled back to the cell surface to continue removing LDL from the blood. If PCSK9 binds, it leads to the degradation of the LDL receptor inside the liver cell.





PRALUENT[®] (alirocumab)

Injection

(evolocumob) Wide Market & Efficacy & Safety Conference on the Safety of Safety & Safety

and every 2 week injectio


Figure 4. A timeline of PCSK9 biology. 20 years ago, PCSK9 was not known to influence cholesterol levels. Today, it's a major drug target that could change the way we treat heart disease. PCSK9 could be a true biomedical science success story, with important contributions from human genetics and other basic science fields paving the way for rational drug development.

http://sitn.hms.harvard.edu/flash/2015/a-potential-new-weapon-against-heart-disease-pcsk9-inhibitors/

no PCSK9 binding to the LDL receptor: • LDL receptor is recycled • more LDL can be removed from blood

Example cell-based assay screen output

Strategy for biochemical kinase assays



NIK phosphorylates IKK- α


Proc. Natl. Acad. Sci. USA Vol. 95, pp. 3792–3797, March 1998 Immunology

NF- κ B-inducing kinase activates IKK- α by phosphorylation of Ser-176

LEI LING, ZHAODAN CAO, AND DAVID V. GOEDDEL*


Tularik, Inc., Two Corporate Drive, South San Francisco, CA 94080

Contributed by David V. Goeddel, January 29, 1998



Phosphorylation of IKK- α (KA) and IKK- β (KA) by NIK. 293 cells were transiently transfected with expression plasmids encoding FLAG epitope-tagged wild-type NIK, IKK- α (KA), or IKK- β (KA). Purified proteins were incubated with [γ -³²P]ATP, resolved by SDS/PAGE, and analyzed by autoradiography. The amounts of proteins used in the reactions were determined by immunoblotting (wb) with anti-FLAG polyclonal antibodies (*Lower*). The positions of IKK- α , IKK- β , and NIK are indicated.

Cell-based NIK assay



B www.biochemj.org


emBio

Biochem. J. (2009) 419, 65-73 (Printed in Great Britain) doi:10.1042/8J20081646

Development of an insect-cell-based assay for detection of kinase inhibition using NF- κ B-inducing kinase as a paradigm

Namir J. HASSAN*12, Sheraz GUL*1, Fiona FLETT*, Edward HOLLINGSWORTH*, Angela A. DUNNE†, Amanda J. EMMONS†, Jonathan P. HUTCHINSON*, 'Martin J. HIBBS*, Susian DVOS*, Jaremy D. KITSONS, Emma HILEY*, Martin RÜDIGER*, David G. TEW*, David J. POWELL* and Mary A. MORSE1

Insect cell-based assay for NIK




BJ	www.biochemj.org	BJ ChemBi

Biochem. J. (2009) 419, 65-73 (Printed in Great Britain) doi:10.1042/8J2008164

Development of an insect-cell-based assay for detection of kinase inhibition using NF- κ B-inducing kinase as a paradigm

Namir J. HASSAN*12, Sheraz GUL*1, Fiona FLETT*, Edward HOLLINGSWORTH*, Angela A. DUNNE†, Amanda J. EMMONS†, Jonathan P. HUTCHINSON*, Martin J. HIBBS*, Susian DYOS*, Jaremy D. KITSONS, Emma HILEY*, Martin RÜDIGER*, David G. TEW*, David J. POWELL* and Mary A. MORSE |


Use of HCS after cell-based NIK inhibitor




+ve control (lymphotoxin)



Hit from cell-based screen





mean pIC50 Cytotoxicity assay (n=2)



Development of an insect-cell-based assay for detection of kinase inhibition using NF- κ B-inducing kinase as a paradigm

Namir J. HASSAN*1-3, Sheraz GUL*1, Fiona FLETT*, Edward HOLLINGSWORTH*, Angela A. DUNNE†, Amanda J. EMMONS†, Jonathan P. HUTCHINSON*, Martin J. HIBBS*, Susan DYOS\$, Jeremy D. KITSONS, Emma HILEY*, Martin RÜDIGER*, David G. TEW*, Javid J. POWELL* and Mary A. MORSE]

Further progression of compounds

Assays	Target value	Comments
Aqueous solubility	>100 µM	Important for running in vitro assays and for in vivo delivery of drug
Log D _{7.4}	0-3 (for BBB penetration ca 2)	A measure of lipophilicity hence movement across membranes
Microsomal stability Cl _{int}	<30 µL·min ^{−1} ·mg ^{−1} protein	Liver microsomes contain membrane bound drug metabolizing enzymes. This assay measures compound clearance and can give an idea of how fast it will be cleared out <i>in vivo</i>
CYP450 inhibition	>10 µM	Main enzymes in body which metabolize drugs and their inhibition can cause toxicity
Caco-2 permeability P _{app}	$>1 \times 10^{-6}$ cm ⁻¹ (asymmetry <2)	Caco-2 colon carcinoma cell line used to estimate permeability across intestinal epithelium, important for drug absorption from gut
MDR1-MDCK permeability Papp	>10 \times 10 ⁻⁶ cm ⁻¹ (asymmetry <2)	MDCK cells transfected with the MDR1 gene, which encodes the efflux protein P glycoprotein (P-gp). An important efflux transporter in many tissues including intestine, kidney and brain, P-gp can be used to predict intestinal and brain permeability
Hep G2 hepatotoxicity	No effect at $50\times IC_{50}$ or EC_{50}	Human HepG2 cells can act as a surrogate for effects of toxicity on human liver, an important cause of drug failure in the clinic
Cytotoxicity in suitable cell line	No effect at $50\times IC_{50}$ or EC_{50}	Reduce the likelyhood of cellular toxicity in vivo



REVIEW Principles of early drug discovery

JP Hughes¹, S Rees², SB Kalindjian³ and KL Philpott³

¹Medlimmune Inc, Granta Park, Cambridge, UK, ²GlaxoSmithiKilne, Gunnels Wood Road, Stevenage, Hertfontshire, UK, and ³King's College, Guy's Campus, London, UK DOI:10.1111/j.1476-5381.2010.01127. www.brjpharmacol.org

Correspondence Dr Karen Philpott, Hodgkin Building, King's College, Guy's Campus, London SE1 1UL, UK. E-mail: karen.philpott@kcl.ac.uk

Keywords drug discovery; high throughput screening: target identification; target validation; hit series; assay development; screening cascade; lead optimization

Received 2 August 2010 Revised 7 October 2010 Accepted 8 November 2010

CONCLUSIONS

- Conformance with industry stand criteria in drug discovery is essential
- Hurdles for achieving Lead and Candidate compound profiles are high
- Develop a panel of assays for each drug discovery screening project
- Use physiologically assay systems if possible
- Develop both biochemical and cell-based assays for any given target
- Develop a panel of assays and pre-screen all against a training compound library
- Ensure post-screening cascade is in place with suitable Secondary assays